Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation

• click to rate

  Posted by Two Blokes May 21, 2025 - Filed in Stock - 5 views
  
  The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.